CLINICAL_TRIALS
trial_result
· 2020-12-03
Clinical Trial Update: Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer [Phase 2]
Summary
Phase 2 open-label study of CS-1008 for untreated and unresectable pancreatic cancer completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-03